Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-
resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to …

Objectives Bedaquiline treatment significantly improves multidrug-resistant tuberculosis
(MDR-TB) patient treatment outcomes. However, safety and efficacy data are lacking for …

Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although
the drug regimens used to treat tuberculosis in these patients are the same as those used in …

Bedaquiline (BDQ) was historically listed by the World Health Organization (WHO) in 2018
as the preferred option for rifampin-resistant tuberculosis (RR-TB) and multidrug-resistant …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Introduction Therapeutic drug monitoring (TDM) has been recommended for treatment
optimization in tuberculosis (TB) but is only is used in certain countries eg USA, Germany …

Background Patients with multidrug-resistant tuberculosis (MDR-TB) face challenges
adhering to medications, given that treatment is prolonged and has a high rate of adverse …

Early diagnosis, including universal drug-susceptibility testing for all patients with
tuberculosis, remains a key priority for tuberculosis elimination by 2035. The drug-resistant …

Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living
with HIV. HIV-associated TB disproportionally affects African countries, particularly …

Objective: This study aims to systematically review the content and potential effects of
clinical pharmacy services in tuberculosis (TB) care management. Methods: Searches were …